Extending range
without compromise
What is RayOne EMV?
An increased range of focus IOL delivering up to 1.5 D of high quality vision.
Up to 1.5 D1 4 6 with an emmetropic target.
Increased range of focus
Truly non-diffractive IOL with monofocal levels of contrast sensitivity 1 , dysphotopsia2 5 and high levels of patient satisfaction.3
High quality vision
Unique positive spherical aberration design provides a smoother transition between distance and near eyes.2 4
Enhanced monovision
1.83° mean IOL rotation 3 to 6 months after surgery. 8
Available on the rotationally stable RayOne toric platform
How does RayOne EMV work?
RayOne EMV is a truly non-diffractive IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses.2
RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration.
Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis.
Centre region
Induced positive spherical aberration.
Blended edge region
Reduced longitudinal spherical aberration designed to maintain visual acuity and constrast sensitivity under mesopic conditions.
Centre region
Induced positive spherical aberration.
Blended edge region
Reduced longitudinal spherical aberration designed to maintain visual acuity and constrast sensitivity under mesopic conditions.
RayOne EMV
with positive spherical aberration
Standard Monofocal IOL
with zero spherical aberration
For illustrative purposes only; refer to clinical data for real world outcomes.
Clinical results with RayOne EMV
An established IOL platform delivering up to 1.5 D of high quality vision1
In a 150-patient double-arm, non-randomized prospective case series, RayOne EMV demonstrated excellent visual outcomes for distance and intermediate vision, and good visual acuity for near vision.
Mean absolute change in lens orientation after 6 months
In a multicenter, randomized, active-controlled FDA trial, RayOne EMV Toric demonstrated a mean absolute change in lens orientation after 6 months of just 1.49° versus Day of Surgery (DOS).
Clinical results with RayOne EMV
RayOne can provide spectacle independence for distance and intermediate vision.¹⁵
RayOne EMV provides improvement in intermediate vision without compromising binocular distance vision.¹²˒¹⁵˒¹⁶
Contrast sensitivity levels similar to standard monofocals in both photopic and mesopic conditions.¹⁰
Since the launch of RayOne EMV in 2020, real world clinical data has demonstrated that:
The following clinical results are from a prospective, single-center, observational, noncomparative study conducted at San Carlos Hospital, Madrid, Spain. The study aimed to evaluate visual and refractive outcomes, as well as patient satisfaction, following bilateral implantation of RayOne EMV (IOL) in 50 eyes, with emmetropia as the target refraction.¹⁶
Outcomes reveal excellent binocular CDVA and good DCIVA, with a high level of patient satisfaction.¹⁶
of patients could read 0.1 logMAR or better
Binocular UDVA
of patients could read 0.2 logMAR or better
Binocular UIVA
Of patients reported no difficulty with their vision in their everyday life (CatQuest-9SF-questionnaire)
Of patients were (very) satisfied with their sight after surgery (CatQuest-9SF-questionnaire)
Comparative outcomes with RayOne EMV
At the Hospital da Luz Lisboa in Lisbon, Professor Filomena Ribeiro and Professor Tiago Ferreira led a 150 patient double-arm, non-randomised prospective case series where RayOne EMV demonstrated excellent visual outcomes for distance and intermediate vision, and good visual acuity for near vision.¹⁰
No statistical difference in contrast sensitivity from a standard monofocal and slightly better contrast sensitivity levels than extended depth of vision (EDOF) IOLs under photopic conditions.¹¹
Patients in the RayOne EMV group experienced a high level of spectacle independence and a photic phenomena profile similar to standard monofocals.¹¹
“RayOne EMV is a solution that gives patients increased satisfaction with the least compromise in their quality of vision.”
Professor Graham Barrett
Developer of RayOne EMV
Learn more about RayOne EMV
Preferred contact from local Rayner representative:
Learn more about RayOne EMV
Thank you for submitting your details, a member of the Rayner team will be in touch soon.
Please visit our main website to discover more about RayOne EMV:
-
Ferreira TB. Comparison of visual outcomes of a monofocal, two enhanced monofocals and two extended depth of focus intraocular lenses. Presented at ESCRS 2022.
-
Rayner RayOne EMV Toric FDA IDE study (G230072).
-
Alcon Clareon Toric Instructions for Use (Rev. 900484016-0624, 2024).
-
Johnson & Johnson Vision TECNIS Eyhance Toric II Instructions for Use (Rev. Z311770E-B, 2022).
The safety and effectiveness of RayOne EMV Toric (RAO210T) has been demonstrated in an FDA IDE trial.
Clinical results are based on clinical studies, including non-randomized and observational data. Patient-reported outcomes may not be representative of all patients.
Individual results may vary depending on patient characteristics, refractive targets, and surgical technique.
CAUTION: United States Federal Law restricts this device to sale and distribution by or on the order of a physician and its use is restricted to a properly licensed physician.